(Q40211075)

18 September 2017

Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR). (English)

1 reference

18 September 2017

Robert D Hubbard

1

1 reference

PubMed ID

17089440

18 September 2017

Julie L Wilsbacher

series ordinal

2

1 reference

18 September 2017

1 January 2007

1 reference

18 September 2017

1 reference

18 September 2017

2

1 reference

18 September 2017

1

1 reference

18 September 2017

41-46

1 reference

Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

18 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

Insulin-like growth factor I receptor signaling in transformation by src oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Strategies to overcome resistance to targeted protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Molecular interactions of the IGF system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

The therapeutic potential of agents targeting the type I insulin-like growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

The insulin-like growth factor-I receptor as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Structure and autoregulation of the insulin-like growth factor 1 receptor kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Regulation of IGF-I receptor signaling in tumor cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Regulatory phosphorylation of Bim: sorting out the ERK from the JNK

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Herceptin: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Substrate competitive inhibitors of IGF-1 receptor kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6-5 ring-fused compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600174

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600174

1 reference

18 September 2017

1 reference

PubMed ID

17089440